# US 11,696,892 B2 · Lipid nanoparticles for delivering modified RNA encoding a VEGF-A polypeptide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,696,892 B2
- Document ID: US11696892B2
- Status: Granted
- Kind: B2
- Application number: 16/760,406
- Filed: 2018-10-31
- Published: 2020-10-29
- Granted: 2023-07-11
- Earliest claimed: 2017-10-31
- Assignees: ModernaTX, Inc.
- Applicants: ModernaTX, Inc.
- Inventors: Kenny Mikael Hansson; Kerry Benenato; Maria Wågberg; Annika Pålsson; Regina Fritsche-Danielson
- Web page: https://patentgrep.com/patent/US11696892B2

## CPC

- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The disclosure relates to nanoparticles comprising a lipid component and a modified RNA encoding a VEGF-A polypeptide. Aspects of the disclosure further relate to uses of nanoparticles comprising a lipid component and a modified RNA encoding a VEGF-A polypeptide, for improving wound healing in a subject.

## Claims

### Claim 1

A lipid nanoparticle comprising
a modified mRNA comprising any one of SEQ ID NOs: 1 or 3-5, encoding a VEGF-A polypeptide of SEQ ID NO: 2.

### Claim 2 (depends on 1)

The lipid nanoparticle of claim 1, wherein the lipid nanoparticle has a mean diameter from about 50 nm to about 100 nm.

### Claim 3

A pharmaceutical composition comprising
(a) at least one lipid nanoparticle comprising
a modified mRNA comprising any one of SEQ ID NOs: 1 or 3-5, encoding a VEGF-A polypeptide of SEQ ID NO: 2; and
(b) a pharmaceutically acceptable excipient.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the lipid nanoparticle has a mean diameter from about 50 nm to about 100 nm.

### Claim 5 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is a solvent, dispersion media, diluent, dispersion, suspension aid, surface active agent, isotonic agent, thickening or emulsifying agent, preservative, polymer, peptide, protein, cell, hyaluronidase, or mixtures thereof.

### Claim 6 (depends on 1)

A method for (i) promoting and/or improving wound healing, (ii) inducing neovascularization, (iii) inducing angiogenesis, or (iv) increasing capillary and/or arteriole density comprising administering to a human subject in need thereof an effective amount of the lipid nanoparticle of claim 1.

### Claim 7 (depends on 6)

The method of claim 6, wherein the lipid nanoparticle has a mean diameter from about 70 nm to about 80 nm.

### Claim 8 (depends on 6)

The method of claim 6, wherein the administration results in a maximum observed plasma and/or tissue concentration (Cmax) of the VEGF-A polypeptide of SEQ ID NO: 2 up to about 450 pg/ml plasma or pg/mg tissue.

### Claim 9 (depends on 6)

The method of claim 6, wherein the administration results in a plasma and/or tissue total area under the concentration curve (AUC0-t) of the VEGF-A polypeptide of SEQ ID NO: 2 up to about 5,500 pg*h/m1 plasma or pg*h/mg tissue.

### Claim 10 (depends on 6)

The method of claim 6, wherein the administration results in the production of more than about 400 pg/mg tissue of the VEGF-A polypeptide of SEQ ID NO: 2 within 8 hours.

### Claim 11 (depends on 6)

The method of claim 6, wherein the administration results in the production of more than about 1 pg/mg tissue of the VEGF-A polypeptide of SEQ ID NO: 2 for up to 6 days.

### Claim 12 (depends on 6)

The method of claim 6, wherein the lipid nanoparticle is administered intradermally.

### Claim 13 (depends on 6)

The method of claim 6, wherein the concentration of the modified mRNA is from about 0.01 mg/kg to about 10 mg/kg.

### Claim 14 (depends on 6)

The method of claim 6, wherein the administration results in an increase of the production of the VEGF-A polypeptide of SEQ ID NO: 2 by a factor of about 5 to about 100, when compared to an administration of the modified mRNA in a citrate saline buffer.

### Claim 15 (depends on 6)

The method of claim 6, wherein the human subject suffers from diabetes.

### Claim 16 (depends on 6)

The method of claim 6, wherein the human subject in need thereof has a wound, and wherein the wound is a surgical wound, a burn, an abrasive wound, a skin biopsy site, a chronic wound, an injury, a graft wound, a diabetic wound, a diabetic ulcer, a pressure ulcer, bed sore, and combinations thereof.
